We are proud to announce that over 45 UK hospitals took part in recruiting participants for the PRISM trial, which is looking to see if giving progesterone can prevent miscarriage in women with early pregnancy bleeding.
The PRISM project team, led by Tommy’s Dr Arri Coomarasamy, recruited women who have suffered miscarriages to join this research trial.
How does the trial work?
PRISM is a randomised, double-blind, placebo-controlled trial:
Randomised: The women who take part will be given either the treatment drug (progesterone) or a placebo – a dummy drug that has no active ingredients. A computer makes the selection so it’s completely random.
Double-blind: The women in the study won’t be told whether they are taking the active medicine or the placebo – and neither will their doctors. So both groups are blinded to this information.
Placebo-controlled: Half the women in the study will have the active medicine and half (the controls) will have the placebo. The medicine that they receive will look exactly the same to them and their doctors, but a completely separate group will keep a record of which women have progesterone and which have the placebo.
By doing the trial in this way, researchers will be able to conclusively test if progesterone has an affect on preventing early miscarriage.
Which centres are taking part?
- Airedale General Hospital
- Birmingham Heartlands Hospital
- Birmingham Women's Hospital
- Bradford Royal Infirmary
- Burnley General Hospital
- Chelsea and Westminster Hospital
- Cumberland Infirmary, Carlisle
- Derriford Hospital, Plymouth
- Glasgow Royal Infirmary
- East Surrey Hospital
- Hinchingbrooke Hospital, Huntingdon
- Hull Royal Infirmary
- James Cook University Hospital, Middlesbrough
- John Radcliffe Hospital, Oxford
- Kings College Hospital
- Liverpool Women's Hospital
- Musgrove Park Hospital, Taunton
- New Cross Hospital, Wolverhampton
- North Devon District Hospital
- Princess Royal Hospital, Telford
- Queen Alexandra Hospital, Portsmouth
- Queen's Hospital, Burton
- Queen's Medical Centre, Nottingham
- Royal Stoke University Hospital
- Royal Victoria Infirmary, Newcastle
- Royal Preston Hospital
- Royal Devon and Exeter Hospital
- Royal Infirmary of Edinburgh
- Scunthorpe General Hospital
- St. James' University Hospital, Leeds
- Sheffield Royal Hallamshire Hospital
- St. Mary's Hospital, London
- St. Mary's Hospital, Manchester
- St. Michael’s University Hospital, Bristol
- St. Peter's Hospital, Chertsey
- St. Thomas's Hospital, London
- Sunderland Royal Hospital
- University College London Hospital
- University Hospital Coventry
- Walsall Manor Hospital
- Warrington Hospital
- West Middlesex University Hospital
- Whipps Cross University Hospital
- Whiston Hospital
- Worcester Royal Hospital
Professor Arri Coomarasamy, Director of Tommy’s National Centre for Miscarriage Research, at the University of Birmingham:
"Miscarriage is a common but deeply personal and often isolating experience for many couples. At the new Tommy's National Centre for Miscarriage Research, we are determined to make a difference. We are committed to understand the causes of miscarriage and find ways to prevent it. Tommy's investment in the new Centre is the best thing that has happened to miscarriage research. It will change many lives."
To read more about the trial at the official PRISM website, click here:
This discovery will help doctors identify the small number of women at most risk who require intervention to prevent stillbirth.
Tommy’s is supporting a nationwide initiative to reduce the number of premature babies who develop cerebral palsy.
Researchers are calling for air pollution levels to be cut in order to protect the health of the next generation.
Data shows differences in stillbirth rates across England, with higher numbers of stillbirths in the most deprived areas.